FDA OKs Teclistamab for Relapsed/Refractory Multiple Myeloma FDA OKs Teclistamab for Relapsed/Refractory Multiple Myeloma
Teclistamab is now an option after progression on triple-class therapy; however, the FDA also issued a Boxed Warning for life-threatening or fatal cytokine release syndrome and neurologic toxicity.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
More News: Brain | Cancer & Oncology | Health | Hematology | Myeloma | Neurology | Toxicology | Warnings